Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease
- PMID: 31631001
- PMCID: PMC6904245
- DOI: 10.1016/j.cmet.2019.09.012
Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease
Abstract
Mild reduction in food intake was recently shown to slow polycystic kidney disease (PKD) progression in mouse models, but whether the effect was due to solely reduced calories or some other aspect of the diet has been unclear. We now show that the benefit is due to the induction of ketosis. Time-restricted feeding, without caloric reduction, strongly inhibits mTOR signaling, proliferation, and fibrosis in the affected kidneys in a PKD rat model. A ketogenic diet had a similar effect and led to regression of renal cystic burden. Acute fasting in rat, mouse, and feline models of PKD results in rapid reduction of cyst volume, while oral administration of the ketone β-hydroxybutyrate (BHB) in rats strongly inhibits PKD progression. These results suggest that cystic cells in PKD are metabolically inflexible, which could be exploited by dietary interventions or supplementation with BHB, representing a new therapeutic avenue to treat PKD.
Keywords: beta-hydroxybutyrate; ketogenic diet; ketosis; metabolic inflexibility; polycystic kidney disease.
Copyright © 2019 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests
JT and TW are listed inventors on a provisional patent application filed by UCSB related to discoveries reported in this paper. TW is an inventor on a patent application by UCSB on a discovery unrelated to this paper. MM reports grants and consulting fees outside the submitted work from Otsuka Pharmaceuticals,Sanofi, and Chinook Therapeutics.
Figures







Comment in
-
Ketosis slows the progression of PKD.Nat Rev Nephrol. 2020 Jan;16(1):1. doi: 10.1038/s41581-019-0226-4. Nat Rev Nephrol. 2020. PMID: 31654043 No abstract available.
References
-
- Bartmann C, Janaki Raman SR, Flöter J, Schulze A, Bahlke K, Willingstorfer J, Strunz M, Wöckel A, Klement RJ, Kapp M, et al. (2018). Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation. Cancer Metab 6. - PMC - PubMed
-
- Brown JH, Bihoreau M-T, Hoffmann S, Kränzlin B, Tychinskaya I, Obermüller N, Podlich D, Boehn SN, Kaisaki PJ, Megel N, et al. (2005). Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J. Am. Soc. Nephrol. JASN 16, 3517–3526. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 DK090728/DK/NIDDK NIH HHS/United States
- UL1 RR024153/RR/NCRR NIH HHS/United States
- U01 DK056957/DK/NIDDK NIH HHS/United States
- UL1 TR000001/TR/NCATS NIH HHS/United States
- M01 RR023940/RR/NCRR NIH HHS/United States
- M01 RR000032/RR/NCRR NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- UL1 TR001417/TR/NCATS NIH HHS/United States
- M01 RR000585/RR/NCRR NIH HHS/United States
- R01 DK113111/DK/NIDDK NIH HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- U01 DK056956/DK/NIDDK NIH HHS/United States
- P30 DK074038/DK/NIDDK NIH HHS/United States
- UL1 TR000165/TR/NCATS NIH HHS/United States
- M01 RR000039/RR/NCRR NIH HHS/United States
- UL1 RR033179/RR/NCRR NIH HHS/United States
- I01 BX004232/BX/BLRD VA/United States
- P30 DK106912/DK/NIDDK NIH HHS/United States
- UL1 TR000135/TR/NCATS NIH HHS/United States
- U01 DK056943/DK/NIDDK NIH HHS/United States
- UL1 RR025777/RR/NCRR NIH HHS/United States
- R01 DK124895/DK/NIDDK NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- U01 DK056961/DK/NIDDK NIH HHS/United States
- UL1 RR025008/RR/NCRR NIH HHS/United States
- R01 DK109563/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous